The European Medicines Agency (EMA) announced, on Wednesday 5 April, following an analysis of the experience acquired during the first five years of operation, that it is proposing new features under the PRIority MEdicines (PRIME) programme.
PRIME was set up to facilitate the development of promising medicines that have the potential to significantly address patients’ unmet medical needs.
Through PRIME, the EMA offers support in the form of scientific and regulatory support to medicine...